Zobrazeno 1 - 10
of 52
pro vyhledávání: '"S Bulova"'
Publikováno v:
Insectes Sociaux. 67:473-479
Extreme temperatures can constrain foraging behavior, and individual differences in thermal tolerances may affect foraging performance within and among species. Ambient temperatures may thus mediate competitive interactions among species that share r
Autor:
Kerry Atkinson, P. Tutschka, K. Downs, Alan J. Concannon, Isadore Brodsky, Jeff Szer, N. Kapoor, J. C. Biggs, P. Crilley, Edward A. Copelan, David Topolsky, B. Avalos, Anthony J. Dodds, S Bulova
Publikováno v:
Scopus-Elsevier
One hundred fifteen patients with chronic myelocytic leukemia (CML) were administered busulphan 4 mg/kg for 4 days and cyclophosphamide 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from histocompatible sibling
Publikováno v:
American Journal of Clinical Oncology. 13:221-225
Veno-occlusive disease (VOD) of the liver is a major complication of bone marrow transplantation (BMT). The overall frequency of VOD has ranged from 20 to 30%, with a mortality rate greater than 40%, as reported by centers utilizing cyclophosphamide
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pamela Crilley, Isadore Brodsky, J Weiss, James F. Conroy, David Topolsky, S Bulova, J Gryn, Kahn Sb
Publikováno v:
American Journal of Clinical Oncology. 14:52-54
Thirteen patients with leukemia were treated with a combination of cytosine arabinoside (ara-C) (3 g/m2 by 1-h infusion every 12 h for 12 doses) and etoposide (100 mg/m2 daily over 1 h for 3 doses). Toxicity of the regimen consisted of severe hematol
Publikováno v:
Bone marrow transplantation. 17(4)
Twenty-five patients with hematologic malignancies were treated with busulfan (16 mg/kg) and cyclophosphamide (50 mg/kg x 3 days) as conditioning for bone marrow transplantation using marrow from serologically matched, DR locus genotypically identica
Publikováno v:
Bone marrow transplantation. 10(5)
We performed a retrospective analysis of 42 consecutive patients undergoing autologous BMT to determine the incidence of second and third degree heart block following the infusion of cryopreserved autologous bone marrow and to identify any predisposi
Autor:
R D, Bigler, P, Crilley, B, Micaily, L W, Brady, D, Topolsky, S, Bulova, E C, Vonderheid, I, Brodsky
Publikováno v:
Bone marrow transplantation. 7(2)
Patients with advanced stage cutaneous T cell lymphoma (CTCL) have a median survival of 2-5 years with no currently available curative therapy. This limited pilot study was performed to determine if CTCL patients could undergo autologous bone marrow
Autor:
Kelch Bp, David Topolsky, Isadore Brodsky, S Bulova, Peter S. Amenta, James F. Conroy, Kahn Sb, Pamela Crilley
Publikováno v:
American journal of clinical oncology. 13(3)
Recurrent leukemia following allogeneic bone marrow transplantation (BMT) for acute nonlymphocytic leukemia (ANLL) continues to be a cause of morbidity and mortality. Most relapses occur within the first 6-12 months, although disease-free survival cu
Publikováno v:
Bone marrow transplantation. 5(3)
Twenty-five consecutive patients with acute myelogenous leukemia (AML) underwent 26 allogeneic bone marrow transplants at Hahnemann University Hospital. Marrow ablation for all patients consisted of busulfan 16 mg/kg and cyclophosphamide 120 mg/kg (B